{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T08:08:37Z","timestamp":1789546117592,"version":"build-2803163510"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Abdom Radiol"],"DOI":"10.1007\/s00261-026-05796-4","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:56:18Z","timestamp":1789545378000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Limited incremental prognostic value of pretreatment MRI and 18F-piflufolastat PET intensity metrics in grade group\u2009\u2265\u20093 prostate cancer"],"prefix":"10.1007","author":[{"given":"Nuttaphon","family":"Aleenajitpong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9123-4010","authenticated-orcid":false,"given":"Rory L.","family":"Cochran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Mercaldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harleen","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6402-7585","authenticated-orcid":false,"given":"Nabih","family":"Nakrour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabela C. S.","family":"Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukesh G.","family":"Harisinghani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"5796_CR1","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.prnil.2024.09.003","volume":"12","author":"G Jung","year":"2024","unstructured":"Jung G, Song B, Ahn H et al (2024) Oncological outcomes after radical prostatectomy of localized prostate cancer: stratified by magnetic resonance imaging and risk classification. Prostate Int 12:224\u2013230. https:\/\/doi.org\/10.1016\/j.prnil.2024.09.003","journal-title":"Prostate Int"},{"key":"5796_CR2","doi-asserted-by":"publisher","first-page":"139","DOI":"10.4274\/dir.2023.232414","volume":"30","author":"\u00d6 \u00d6nder","year":"2024","unstructured":"\u00d6nder \u00d6, Ayva M, Yara\u015f\u0131r Y et al (2024) Long-term follow-up results of multiparametric prostate MRI and the prognostic value of PI-RADS: a single-center retrospective cohort study. Diagn Interv Radiol 30:139\u2013151. https:\/\/doi.org\/10.4274\/dir.2023.232414","journal-title":"Diagn Interv Radiol"},{"key":"5796_CR3","doi-asserted-by":"publisher","first-page":"7150","DOI":"10.3390\/jcm14207150","volume":"14","author":"AE Ata\u015f","year":"2025","unstructured":"Ata\u015f AE, Kerimo\u011flu \u00dc, \u0130lhan Z et al (2025) Predictive value of quantitative ADC, SUVmax, and the SUVmax\/ADC ratio for biological behavior and prognosis in high-risk prostate cancer. J Clin Med 14:7150. https:\/\/doi.org\/10.3390\/jcm14207150","journal-title":"J Clin Med"},{"key":"5796_CR4","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ et al (2020) Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 395:1208\u20131216. https:\/\/doi.org\/10.1016\/S0140-6736(20)30314-7","journal-title":"Lancet"},{"key":"5796_CR5","doi-asserted-by":"publisher","first-page":"3610","DOI":"10.1007\/s00261-023-04002-z","volume":"48","author":"S Houshmand","year":"2023","unstructured":"Houshmand S, Lawhn-Heath C, Behr S (2023) PSMA PET imaging in the diagnosis and management of prostate cancer. Abdom Radiol (NY) 48:3610\u20133623. https:\/\/doi.org\/10.1007\/s00261-023-04002-z","journal-title":"Abdom Radiol (NY)"},{"key":"5796_CR6","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/1754-9485.13787","volume":"69","author":"A Ades","year":"2025","unstructured":"Ades A, Holt T, Rhee H, Webb M, Mehdi AM, Ratnayake G (2025) Prognostic value of PSMA PET in predicting long-term biochemical control following curative intent treatment for prostate cancer. J Med Imaging Radiat Oncol 69:129\u2013135. https:\/\/doi.org\/10.1111\/1754-9485.13787","journal-title":"J Med Imaging Radiat Oncol"},{"key":"5796_CR7","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.1007\/s00259-022-05756-2","volume":"49","author":"MJ Roberts","year":"2022","unstructured":"Roberts MJ, Morton A, Papa N et al (2022) Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy. Eur J Nucl Med Mol Imaging 49:3289\u20133294. https:\/\/doi.org\/10.1007\/s00259-022-05756-2","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5796_CR8","doi-asserted-by":"publisher","first-page":"94","DOI":"10.2967\/jnumed.123.266164","volume":"65","author":"L Emmett","year":"2024","unstructured":"Emmett L, Papa N, Counter W et al (2024) Reproducibility and accuracy of the PRIMARY score on PSMA PET and of PI-RADS on multiparametric MRI for prostate cancer diagnosis within a real-world database. J Nucl Med 65:94\u201399. https:\/\/doi.org\/10.2967\/jnumed.123.266164","journal-title":"J Nucl Med"},{"key":"5796_CR9","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.2967\/jnumed.121.263448","volume":"63","author":"L Emmett","year":"2022","unstructured":"Emmett L, Papa N, Buteau J et al (2022) The PRIMARY score: using intraprostatic [68Ga]Ga-PSMA PET\/CT patterns to optimize prostate cancer diagnosis. J Nucl Med 63:1644\u20131650. https:\/\/doi.org\/10.2967\/jnumed.121.263448","journal-title":"J Nucl Med"},{"key":"5796_CR10","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.eururo.2025.08.005","volume":"89","author":"K Herrmann","year":"2026","unstructured":"Herrmann K, Walz J, MacLennan S et al (2026) SPARC: the Standardised Prostate-specific Membrane Antigen Positron Emission Tomography\/Computed Tomography Analysis and Reporting Consensus: a Delphi analysis. Eur Urol 89:260\u2013274. https:\/\/doi.org\/10.1016\/j.eururo.2025.08.005","journal-title":"Eur Urol"},{"key":"5796_CR11","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S1470-2045(26)00120-8","volume":"27","author":"JP Buteau","year":"2026","unstructured":"Buteau JP, Moon D, Fahey MT et al (2026) Effect of [68Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trial. Lancet Oncol 27:839\u2013848. https:\/\/doi.org\/10.1016\/S1470-2045(26)00120-8","journal-title":"Lancet Oncol"},{"key":"5796_CR12","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13014-024-02483-w","volume":"19","author":"S Bela Andela","year":"2024","unstructured":"Bela Andela S, Amthauer H, Furth C et al (2024) Quantitative PSMA-PET parameters in localized prostate cancer: prognostic and potential predictive value. Radiat Oncol 19:97. https:\/\/doi.org\/10.1186\/s13014-024-02483-w","journal-title":"Radiat Oncol"},{"key":"5796_CR13","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s40644-025-00907-8","volume":"25","author":"R Chen","year":"2025","unstructured":"Chen R, Li Y, Liang D, Liu J, Sun T (2025) PSMA-PET-derived distance features as biomarkers for predicting outcomes in primary prostate cancer post-radical prostatectomy. Cancer Imaging 25:93. https:\/\/doi.org\/10.1186\/s40644-025-00907-8","journal-title":"Cancer Imaging"},{"key":"5796_CR14","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.3390\/cancers17132249","volume":"17","author":"K Kudura","year":"2025","unstructured":"Kudura K, Schaulin Y, Templeton AJ et al (2025) Tumor segmentation on PSMA PET\/CT predicts survival in biochemical recurrence of prostate cancer: a retrospective study using [68Ga]Ga-PSMA-11 and [18F]-PSMA-1007. Cancers (Basel) 17:2249. https:\/\/doi.org\/10.3390\/cancers17132249","journal-title":"Cancers (Basel)"},{"key":"5796_CR15","doi-asserted-by":"publisher","unstructured":"Epstein JI, Egevad L, Amin MB et al (2016) The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol 40:244\u2013252. https:\/\/doi.org\/10.1097\/PAS.0000000000000530","DOI":"10.1097\/PAS.0000000000000530"},{"key":"5796_CR16","unstructured":"National Comprehensive Cancer Network (2026) NCCN clinical practice guidelines in oncology (NCCN Guidelines): prostate cancer. Version 5.2026. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1459. Accessed 2 February 2026"},{"key":"5796_CR17","volume-title":"AJCC cancer staging manual","year":"2017","unstructured":"Amin MB, Edge SB, Greene FL et al (eds) (2017) AJCC cancer staging manual, 8th edn. Springer, New York","edition":"8"},{"key":"5796_CR18","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1200\/JCO.2015.65.7270","volume":"34","author":"S Halabi","year":"2016","unstructured":"Halabi S, Kelly WK, Ma H et al (2016) Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer. J Clin Oncol 34:1652\u20131659. https:\/\/doi.org\/10.1200\/JCO.2015.65.7270","journal-title":"J Clin Oncol"},{"key":"5796_CR19","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.euo.2022.10.002","volume":"6","author":"HA de Barros","year":"2023","unstructured":"de Barros HA, van Beurden I, Droghetti M et al (2023) Role of local and\/or metastasis-directed therapy in patients with hormone-sensitive M1a prostate cancer: a systematic review. Eur Urol Oncol 6:16\u201327. https:\/\/doi.org\/10.1016\/j.euo.2022.10.002","journal-title":"Eur Urol Oncol"},{"key":"5796_CR20","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1002\/bco2.73","volume":"2","author":"S Aluwini","year":"2021","unstructured":"Aluwini S, Oprea-Lager DE, de Barros H et al (2021) M1a prostate cancer: results of a Dutch multidisciplinary consensus meeting. BJUI Compass 2:159\u2013168. https:\/\/doi.org\/10.1002\/bco2.73","journal-title":"BJUI Compass"},{"key":"5796_CR21","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","volume":"76","author":"B Turkbey","year":"2019","unstructured":"Turkbey B, Rosenkrantz AB, Haider MA et al (2019) Prostate Imaging Reporting and Data System version 2.1: 2019 update of Prostate Imaging Reporting and Data System version 2. Eur Urol 76:340\u2013351. https:\/\/doi.org\/10.1016\/j.eururo.2019.02.033","journal-title":"Eur Urol"},{"key":"5796_CR22","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1148\/radiol.2018181278","volume":"290","author":"S Mehralivand","year":"2019","unstructured":"Mehralivand S, Shih JH, Harmon S et al (2019) A grading system for the assessment of risk of extraprostatic extension of prostate cancer at multiparametric MRI. Radiology 290:709\u2013719. https:\/\/doi.org\/10.1148\/radiol.2018181278","journal-title":"Radiology"},{"key":"5796_CR23","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s11604-014-0367-0","volume":"32","author":"R Itatani","year":"2014","unstructured":"Itatani R, Namimoto T, Yoshimura A et al (2014) Clinical utility of the normalized apparent diffusion coefficient for preoperative evaluation of the aggressiveness of prostate cancer. Jpn J Radiol 32:685\u2013691. https:\/\/doi.org\/10.1007\/s11604-014-0367-0","journal-title":"Jpn J Radiol"},{"key":"5796_CR24","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1007\/s00330-024-10890-6","volume":"35","author":"G Agrotis","year":"2025","unstructured":"Agrotis G, Pooch E, Abdelatty M et al (2025) Diagnostic performance of ADC and ADCratio in MRI-based prostate cancer assessment: a systematic review and meta-analysis. Eur Radiol 35:404\u2013416. https:\/\/doi.org\/10.1007\/s00330-024-10890-6","journal-title":"Eur Radiol"},{"key":"5796_CR25","doi-asserted-by":"publisher","first-page":"W585","DOI":"10.2214\/AJR.15.14338","volume":"205","author":"T Barrett","year":"2015","unstructured":"Barrett T, Priest AN, Lawrence EM et al (2015) Ratio of tumor to normal prostate tissue apparent diffusion coefficient as a method for quantifying DWI of the prostate. AJR Am J Roentgenol 205:W585\u2013W593. https:\/\/doi.org\/10.2214\/AJR.15.14338","journal-title":"AJR Am J Roentgenol"},{"key":"5796_CR26","doi-asserted-by":"publisher","first-page":"W134","DOI":"10.2214\/AJR.19.21365","volume":"213","author":"AM Bajgiran","year":"2019","unstructured":"Bajgiran AM, Mirak SA, Sung K et al (2019) Apparent diffusion coefficient (ADC) ratio versus conventional ADC for detecting clinically significant prostate cancer with 3-T MRI. AJR Am J Roentgenol 213:W134\u2013W142. https:\/\/doi.org\/10.2214\/AJR.19.21365","journal-title":"AJR Am J Roentgenol"},{"key":"5796_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41824-024-00234-4","volume":"9","author":"E Hvittfeldt","year":"2025","unstructured":"Hvittfeldt E, Hedeer F, Thimansson E et al (2025) Semi-standardized evaluation of extraprostatic extension and seminal vesicle invasion with [18F]PSMA-1007 PET\/CT: a comparison to MRI using histopathology as reference. EJNMMI Rep 9:1. https:\/\/doi.org\/10.1186\/s41824-024-00234-4","journal-title":"EJNMMI Rep"},{"key":"5796_CR28","doi-asserted-by":"publisher","first-page":"5274","DOI":"10.1007\/s00261-025-04948-2","volume":"50","author":"S Woo","year":"2025","unstructured":"Woo S, Freedman D, Becker AS et al (2025) Evaluating extraprostatic extension of prostate cancer: pragmatic integration of MRI and PSMA-PET\/CT. Abdom Radiol (NY) 50:5274\u20135282. https:\/\/doi.org\/10.1007\/s00261-025-04948-2","journal-title":"Abdom Radiol (NY)"},{"key":"5796_CR29","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1007\/s00330-025-11358-x","volume":"35","author":"S Woo","year":"2025","unstructured":"Woo S, Becker AS, Leithner D et al (2025) Discordance between prostate MRI and PSMA-PET\/CT: the next big challenge for primary prostate tumor assessment? Eur Radiol 35:4043\u20134054. https:\/\/doi.org\/10.1007\/s00330-025-11358-x","journal-title":"Eur Radiol"},{"key":"5796_CR30","doi-asserted-by":"publisher","first-page":"847","DOI":"10.2967\/jnumed.121.262398","volume":"63","author":"I Sonni","year":"2022","unstructured":"Sonni I, Felker ER, Lenis AT et al (2022) Head-to-head comparison of [68Ga]Ga-PSMA-11 PET\/CT and mpMRI with a histopathology gold standard in the detection, intraprostatic localization, and determination of local extension of primary prostate cancer: results from a prospective single-center imaging trial. J Nucl Med 63:847\u2013854. https:\/\/doi.org\/10.2967\/jnumed.121.262398","journal-title":"J Nucl Med"},{"key":"5796_CR31","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.juro.2006.10.097","volume":"177","author":"MS Cookson","year":"2007","unstructured":"Cookson MS, Aus G, Burnett AL et al (2007) Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 177:540\u2013545. https:\/\/doi.org\/10.1016\/j.juro.2006.10.097","journal-title":"J Urol"},{"key":"5796_CR32","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/cncr.23139","volume":"112","author":"MC Abramowitz","year":"2008","unstructured":"Abramowitz MC, Li T, Buyyounouski MK et al (2008) The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer. Cancer 112:55\u201360. https:\/\/doi.org\/10.1002\/cncr.23139","journal-title":"Cancer"},{"key":"5796_CR33","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM et al (2016) Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol 34:1402\u20131418. https:\/\/doi.org\/10.1200\/JCO.2015.64.2702","journal-title":"J Clin Oncol"},{"key":"5796_CR34","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"5796_CR35","doi-asserted-by":"publisher","first-page":"10079","DOI":"10.1038\/s41598-023-36685-1","volume":"13","author":"A Fujimoto","year":"2023","unstructured":"Fujimoto A, Sakamoto S, Horikoshi T et al (2023) Tumor localization by Prostate Imaging and Reporting and Data System (PI-RADS) version 2.1 predicts prognosis of prostate cancer after radical prostatectomy. Sci Rep 13:10079. https:\/\/doi.org\/10.1038\/s41598-023-36685-1","journal-title":"Sci Rep"},{"key":"5796_CR36","doi-asserted-by":"publisher","first-page":"913","DOI":"10.2214\/AJR.19.22653","volume":"215","author":"N Shin","year":"2020","unstructured":"Shin N, Park SY (2020) Postoperative biochemical failure in patients with PI-RADS category 4 or 5 prostate cancers: risk stratification according to zonal location of an index lesion. AJR Am J Roentgenol 215:913\u2013919. https:\/\/doi.org\/10.2214\/AJR.19.22653","journal-title":"AJR Am J Roentgenol"},{"key":"5796_CR37","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.2214\/AJR.11.6861","volume":"197","author":"A Oto","year":"2011","unstructured":"Oto A, Yang C, Kayhan A et al (2011) Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis. AJR Am J Roentgenol 197:1382\u20131390. https:\/\/doi.org\/10.2214\/AJR.11.6861","journal-title":"AJR Am J Roentgenol"},{"key":"5796_CR38","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1148\/radiol.11091409","volume":"259","author":"T Hambrock","year":"2011","unstructured":"Hambrock T, Somford DM, Huisman HJ et al (2011) Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology 259:453\u2013461. https:\/\/doi.org\/10.1148\/radiol.11091409","journal-title":"Radiology"},{"key":"5796_CR39","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.eururo.2015.06.046","volume":"69","author":"JI Epstein","year":"2016","unstructured":"Epstein JI, Zelefsky MJ, Sjoberg DD et al (2016) A contemporary prostate cancer grading system: a validated alternative to the Gleason score. Eur Urol 69:428\u2013435. https:\/\/doi.org\/10.1016\/j.eururo.2015.06.046","journal-title":"Eur Urol"},{"key":"5796_CR40","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/j.1464-410X.2012.11611.x","volume":"111","author":"PM Pierorazio","year":"2013","unstructured":"Pierorazio PM, Walsh PC, Partin AW, Epstein JI (2013) Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int 111:753\u2013760. https:\/\/doi.org\/10.1111\/j.1464-410X.2012.11611.x","journal-title":"BJU Int"},{"key":"5796_CR41","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1111\/j.1464-410X.2006.06148.x","volume":"97","author":"BA Nelson","year":"2006","unstructured":"Nelson BA, Shappell SB, Chang SS et al (2006) Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer. BJU Int 97:1169\u20131172. https:\/\/doi.org\/10.1111\/j.1464-410X.2006.06148.x","journal-title":"BJU Int"},{"key":"5796_CR42","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.ejca.2006.10.018","volume":"43","author":"FKH Chun","year":"2007","unstructured":"Chun FKH, Briganti A, Jeldres C et al (2007) Tumour volume and high grade tumour volume are the best predictors of pathologic stage and biochemical recurrence after radical prostatectomy. Eur J Cancer 43:536\u2013543. https:\/\/doi.org\/10.1016\/j.ejca.2006.10.018","journal-title":"Eur J Cancer"},{"key":"5796_CR43","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1097\/PAS.0000000000001291","volume":"43","author":"Y Ito","year":"2019","unstructured":"Ito Y, Vertosick EA, Sjoberg DD et al (2019) In organ-confined prostate cancer, tumor quantitation not found to aid in prediction of biochemical recurrence. Am J Surg Pathol 43:1061\u20131065. https:\/\/doi.org\/10.1097\/PAS.0000000000001291","journal-title":"Am J Surg Pathol"},{"key":"5796_CR44","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/s00259-022-05931-5","volume":"50","author":"SKB Spohn","year":"2022","unstructured":"Spohn SKB, Farolfi A, Schandeler S et al (2022) The maximum standardized uptake value in patients with recurrent or persistent prostate cancer after radical prostatectomy and PSMA-PET-guided salvage radiotherapy: a multicenter retrospective analysis. Eur J Nucl Med Mol Imaging 50:218\u2013227. https:\/\/doi.org\/10.1007\/s00259-022-05931-5","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5796_CR45","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.2967\/jnumed.122.265368","volume":"64","author":"M Chen","year":"2023","unstructured":"Chen M, Fu Y, Peng S et al (2023) The association between [68Ga]PSMA PET\/CT response and biochemical progression in patients with high-risk prostate cancer receiving neoadjuvant therapy. J Nucl Med 64:1550\u20131555. https:\/\/doi.org\/10.2967\/jnumed.122.265368","journal-title":"J Nucl Med"},{"key":"5796_CR46","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/S1470-2045(26)00016-1","volume":"27","author":"MJ Karpinski","year":"2026","unstructured":"Karpinski MJ, Civan C, Rauscher I et al (2026) New prostate cancer risk groups by PSMA-PET (PPP3): an international, retrospective, registry-based cohort study. Lancet Oncol 27:480\u2013490. https:\/\/doi.org\/10.1016\/S1470-2045(26)00016-1","journal-title":"Lancet Oncol"},{"key":"5796_CR47","doi-asserted-by":"publisher","first-page":"e0235779","DOI":"10.1371\/journal.pone.0235779","volume":"15","author":"K Sandeman","year":"2020","unstructured":"Sandeman K, Eineluoto JT, Pohjonen J et al (2020) Prostate MRI added to CAPRA, MSKCC and Partin cancer nomograms significantly enhances the prediction of adverse findings and biochemical recurrence after radical prostatectomy. PLoS One 15:e0235779. https:\/\/doi.org\/10.1371\/journal.pone.0235779","journal-title":"PLoS One"},{"key":"5796_CR48","doi-asserted-by":"publisher","first-page":"4223","DOI":"10.1007\/s00330-025-11360-3","volume":"35","author":"F Kleiburg","year":"2025","unstructured":"Kleiburg F, de Geus-Oei LF, Spijkerman R et al (2025) Baseline PSMA PET\/CT parameters predict overall survival and treatment response in metastatic castration-resistant prostate cancer patients. Eur Radiol 35:4223\u20134232. https:\/\/doi.org\/10.1007\/s00330-025-11360-3","journal-title":"Eur Radiol"}],"container-title":["Abdominal Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-026-05796-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00261-026-05796-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-026-05796-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:56:22Z","timestamp":1789545382000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00261-026-05796-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":48,"alternative-id":["5796"],"URL":"https:\/\/doi.org\/10.1007\/s00261-026-05796-4","relation":{},"ISSN":["2366-0058"],"issn-type":[{"value":"2366-0058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"assertion":[{"value":"16 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}